<DOC>
	<DOCNO>NCT02359227</DOCNO>
	<brief_summary>Planned enrollment approximately twelve subject stable chronic heart failure . Enrolled subject receive eight sequential day continuous , stepwise , dose increase , subcutaneous ( SQ ) infusion open-label cenderitide via Insulet Drug Delivery System . Planned infusion rate cenderitide administered subject continuously four , 48-hour infusion period .</brief_summary>
	<brief_title>Safety Study Cenderitide Stable Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Key Male female , ≥ 18 year age Body Mass Index ( BMI ) 1840 kg/m2 , inclusive Current historical New York Heart Association ( NYHA ) functional class ≥ II At least one following : document systolic heart failure ejection fraction ( EF ) ≤ 40 % and/or historical measurement plasma BNP ≥ 150 pg/mL ( NTproBNP ≥ 600 pg/mL ) Systolic blood pressure 100160 mmHg Stable compliant treatment oral heart failure medication least 4 week prior Screening Key Known hypersensitivity allergy natriuretic peptide component , nesiritide , natriuretic peptide related compound Current clinical diagnosis acute decompensated heart failure ( ADHF ) Clinical diagnosis acute coronary syndrome ( ACS ) within 30 day prior Screening . Symptomatic postural hypotension Evidence uncorrected volume sodium ≤ 130 mmol/L condition would predispose patient adverse event Clinically significant aortic mitral valve stenosis Acute myocarditis hypertrophic obstructive , restrictive , constrictive cardiomyopathy ( include restrictive mitral filling pattern ) Severe renal failure define creatinine clearance &lt; 45 mL/min estimate either CockcroftGault MDRD equation Significant pulmonary disease ( e.g. , history oral daily steroid dependency , history Carbon Dioxide ( CO2 ) retention need intubation acute exacerbation , currently receive IV steroid ) Known hepatic impairment indicate follow : A ) total bilirubin &gt; 3 mg/dL ; B ) albumin &lt; 2.8 mg/dL , sign symptom hepatic dysfunction ; C ) increase ammonia level , perform , sign symptom hepatic dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Natriuretic Peptides</keyword>
	<keyword>Cenderitide</keyword>
</DOC>